Drug reference
alogliptin-pioglitazone
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Endocrine (Insulin sensitizers)
Mechanism of action
Alogliptin: Selective dipeptidyl peptidase-4 (DPP-4) inhibitor; slows inactivation of incretin hormones (eg, GLP-1, GIP), thereby reducing fasting and postprandial glucose concentrations in a glucose-dependent manner Pioglitazone: Thiazolidinedione; improves target cell response to insulin; decreases hepatic gluconeogenesis
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Back pain
- Hypoglycemia
- Edema when used in combination with sulfonylurea
- Worsening CHF
- Pancreatitis
Related conditions
Frequently asked questions
What drug class is alogliptin-pioglitazone?
alogliptin-pioglitazone belongs to: Endocrine.
How does alogliptin-pioglitazone work?
Alogliptin: Selective dipeptidyl peptidase-4 (DPP-4) inhibitor; slows inactivation of incretin hormones (eg, GLP-1, GIP), thereby reducing fasting and postprandial glucose concentrations in a glucose-dependent manner Pioglitazone: Thiazolidinedione; improves target cell response to insulin; decreases hepatic gluconeogenesis
What are the common side effects of alogliptin-pioglitazone?
Upper respiratory tract infection, Nasopharyngitis, Back pain, Hypoglycemia, Edema when used in combination with sulfonylurea, Worsening CHF, Pancreatitis
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.